{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:42:28Z","timestamp":1780656148787,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cjca.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:18:27Z","timestamp":1741346307000},"page":"939-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early Potentially Irreversible Cardiac Damage in Fabry Disease Precedes Gb3 Inclusion Body Formation"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-6938","authenticated-orcid":false,"given":"Chung-Lin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Sin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Tzu","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Fu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dau-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2025.03.001_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjca.2025.03.001_bib2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ymgme.2019.07.012","article-title":"Founder effect of Fabry disease due to p.F113L mutation: clinical profile of a late-onset phenotype","volume":"129","author":"Azevedo","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cjca.2025.03.001_bib3","article-title":"Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation","volume":"22","author":"Azevedo","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.cjca.2025.03.001_bib4","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.3390\/ijms22094434","article-title":"Fabry disease and the heart: a comprehensive review","volume":"22","author":"Azevedo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2025.03.001_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cjca.2025.03.001_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1750-1172-9-96","article-title":"Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4\u00a0+ 919G > A)","volume":"9","author":"Hsu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjca.2025.03.001_bib7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Kramer","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2025.03.001_bib8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.03.001_bib9","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.03.001_bib10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41436-018-0010-z","article-title":"Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients","volume":"21","author":"Hsu","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.cjca.2025.03.001_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BJ20130825","article-title":"A\u00a0symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis","volume":"456","author":"Taguchi","year":"2013","journal-title":"Biochem J"},{"key":"10.1016\/j.cjca.2025.03.001_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jb\/mvq125","article-title":"Increased globotriaosylceramide levels in a transgenic mouse expressing human \u03b11,4-galactosyltransferase and a mouse model for treating Fabry disease","volume":"149","author":"Shiozuka","year":"2011","journal-title":"J\u00a0Biochem"},{"key":"10.1016\/j.cjca.2025.03.001_bib13","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"Alpha-galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cjca.2025.03.001_bib14","first-page":"1664","article-title":"Biomarkers in Fabry disease. Implications for clinical diagnosis and follow-up","volume":"10","author":"Carnicer-C\u00e1ceres","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cjca.2025.03.001_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2119\/molmed.2014.00034","article-title":"Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure","volume":"20","author":"O\u2019Brien","year":"2014","journal-title":"Mol Med"},{"key":"10.1016\/j.cjca.2025.03.001_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1385\/CT:3:2:119","article-title":"Distinct roles of p42\/p44(ERK) and p38 MAPK in oxidant-induced AP-1 activation and cardiomyocyte hypertrophy","volume":"3","author":"Tu","year":"2003","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.cjca.2025.03.001_bib17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.humpath.2015.07.017","article-title":"Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy","volume":"46","author":"Chimenti","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cjca.2025.03.001_bib18","doi-asserted-by":"crossref","first-page":"e22716","DOI":"10.1002\/jbt.22716","article-title":"Proanthocyanidin alleviates doxorubicin-induced cardiac injury by inhibiting NF-kB pathway and modulating oxidative stress, cell cycle, and fibrogenesis","volume":"35","author":"Sadek","year":"2021","journal-title":"J\u00a0Biochem Mol Toxicol"},{"key":"10.1016\/j.cjca.2025.03.001_bib19","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.3390\/ijms23052617","article-title":"The pathogenesis of cardiac fibrosis: a review of recent progress","volume":"23","author":"Maruyama","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2025.03.001_bib20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","article-title":"Manifestations of Fabry disease in placental tissue","volume":"29","author":"Vedder","year":"2006","journal-title":"J\u00a0Inherit Metab Dis"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25001801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25001801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:56:52Z","timestamp":1760072212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X25001801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0828282X25001801"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2025.03.001","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Potentially Irreversible Cardiac Damage in Fabry Disease Precedes Gb3 Inclusion Body Formation","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}